Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73–84.

Article  PubMed  Google Scholar 

Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80:1511–21.

Article  PubMed  Google Scholar 

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.

Article  PubMed  Google Scholar 

Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52:1000–8.

Article  PubMed  Google Scholar 

Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770–6.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Strand V, Kay J, Braun J. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75:791–4.

Article  CAS  PubMed  Google Scholar 

Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18:205–16.

Article  PubMed  Google Scholar 

Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford). 2020;59(Suppl 4):79–89.

Article  Google Scholar 

Toussirot E. Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. Drugs Aging. 2010;27:523–31.

Article  CAS  PubMed  Google Scholar 

Toussirot E. Diagnosis and management of late-onset spondyloarthritis: implications of treat-to-target recommendations. Drugs Aging. 2015;32:515–24.

Article  CAS  PubMed  Google Scholar 

Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol. 1989;16:1214–7.

CAS  PubMed  Google Scholar 

Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis. 1997;56:176–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olivieri I, Padula A, Pierro A, Favaro L, Oranges GS, Ferri S. Late onset seronegative spondylarthopathy. J Rheumatol. 1995;22:899–903.

CAS  PubMed  Google Scholar 

Endo Y, Fujikawa K, Koga T, Mizokami A, Mine M, Tsukada T, et al. Characteristics of late-onset spondyloarthritis in Japan: a retrospective cohort study. Medicine (Baltimore). 2019;98: e14431.

Article  CAS  PubMed  Google Scholar 

Chung HY, Huang JX, Chan SCW, Lee KH, Tsang HHL, Lau CS. Clinical, radiological, and magnetic resonance imaging characteristics of axial spondyloarthritis with late onset. Medicine (Baltimore). 2022;101: e29523.

Article  CAS  PubMed  Google Scholar 

Mougui A, Baba Z, Hmamouchi I, Abouqal R, Bezza A, Allali F, et al. Characteristics of late-onset spondyloarthritis: data from the moroccan registry of biological therapies in rheumatic diseases. Cureus. 2023;15: e39100.

PubMed  PubMed Central  Google Scholar 

Ortolan A, Webers C, Sepriano A, Falzon L, Baraliakos X, Landewé RB, et al. Efficacy and safety of non-pharmacologicaland non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82:142–52.

Article  CAS  PubMed  Google Scholar 

Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008; 2008: CD002822.

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285–99.

Article  PubMed  PubMed Central  Google Scholar 

Zochling J, Bohl-Bühler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol. 2006;25:794–800.

Article  PubMed  Google Scholar 

Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015; 2015: CD010952.

Wanders A, van der Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756–65.

Article  CAS  PubMed  Google Scholar 

Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75:1438–43.

Article  CAS  PubMed  Google Scholar 

Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74:1241–8.

Article  CAS  PubMed  Google Scholar 

Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, et al. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78:1536–44.

Article  PubMed  Google Scholar 

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78:1167–78.

Article  CAS  PubMed  Google Scholar 

McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395:1496–505.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123–31.

Article  CAS  PubMed  Google Scholar 

Baraliakos X, Østergaard M, Poddubnyy D, der Heijde DV, Deodhar A, Machado P, et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomised phase iiib study. Ann Rheum Dis. 2023;82(Suppl 1):38–40.

Google Scholar 

Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92: e12946.

Article  PubMed  Google Scholar 

Fauny M, Moulin D, D’Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79:1132–8.

Article  CAS  PubMed  Google Scholar 

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48.

Article  CAS  PubMed  Google Scholar 

Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285.

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Ma J, Ge J, Wang B, Yue D, Wang W. Short-term efficacy and safety of secukinumab for ankylosing spondylitis: a systematic review and meta-analysis of RCTs. Mediat Inflamm. 2020;2020:1639016.

Article  Google Scholar 

Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76:571–9.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol (Hoboken NJ). 2021;73:110–20.

Article  CAS  Google Scholar 

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395:53–64.

Article  CAS  PubMed  Google Scholar 

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441–51.

Article  PubMed